rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Celcuity Inc.

CELC · Nasdaq

Health CareBiotechnologyNot moving yet

CELC stood above a rising 150-day average in 32 of the last 52 weekly readings, and has been out of that trend for the last 20 weeks. It is 43.8% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 20
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$652.8M
Officials’ trades on record
4
Institutions holding
262 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 32 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$612.3M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

4 disclosed lines: House 4, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Tom Malinowski House: U.S. House ClerkNJ07sold$1k–$15k26 May 2021filed 23 Jun 2021
Tom Malinowski House: U.S. House ClerkNJ07bought$1k–$15k23 Jun 2020filed 26 Aug 2021
Tom Malinowski House: U.S. House ClerkNJ07bought$1k–$15k22 Jun 2020filed 26 Aug 2021
Tom Malinowski House: U.S. House ClerkNJ07bought$1k–$15k18 Jun 2020filed 5 Mar 2021

Insiders

Buy orders, 12 months0
Sale orders, 12 months10
Buyers · sellers0 · 4
WhoDidSharesTraded
Baker Bros. Advisors LpOthersold261,368at $102.5014 Jul 2026filed 16 Jul 2026
Baker Bros. Advisors LpOthersold2,838,632at $102.5014 Jul 2026filed 16 Jul 2026
David DalveyDirectorsold25,000at $140.684 May 2026filed 6 May 2026
Richard E. BullerDirectorsold1,289at $137.004 May 2026filed 6 May 2026
Richard E. BullerDirectorsold550at $139.004 May 2026filed 6 May 2026
Richard E. BullerDirectorsold1,670at $139.584 May 2026filed 6 May 2026
Richard E. BullerDirectorsold2,301at $141.034 May 2026filed 6 May 2026
Richard E. BullerDirectorsold2,825at $142.044 May 2026filed 6 May 2026
Richard E. BullerDirectorsold365at $143.244 May 2026filed 6 May 2026
Richard E. BullerDirectorsold2,325at $110.1131 Mar 2026filed 2 Apr 2026
Richard E. BullerDirectorsold675at $110.8331 Mar 2026filed 2 Apr 2026
David DalveyDirectorsold20,000at $120.0327 Jan 2026filed 29 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders262+0 on the quarter
New · exited61 · 60
Reported value$5.8B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BAKER BROS. ADVISORS LPunchanged · filed 14 Aug 20267,915,792$828.2M00.0%
Avoro Capital Advisors LLCadded · filed 14 Aug 20263,400,000$355.7M+25,000+0.7%
RTW INVESTMENTS, LPadded · filed 14 Aug 20263,304,903$345.8M+265,282+8.7%
PERCEPTIVE ADVISORS LLCadded · filed 14 Aug 20263,197,200$334.5M+70,000+2.2%
BlackRock, Inc.added · filed 7 Aug 20263,018,785$315.8M+307,253+11.3%
STATE STREET CORPadded · filed 7 Aug 20261,955,304$204.6M+436,599+28.7%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,874,137$196.1M+91,243+5.1%
NEA Management Company, LLCreduced · filed 14 Aug 20261,710,561$179.0M-575,000−25.2%
Soleus Capital Management, L.P.added · filed 11 Aug 20261,704,318$178.3M+419,940+32.7%
BANK OF AMERICA CORPadded · filed 14 Aug 20261,471,307$153.9M+756,978+106.0%
31 Mar 2023 – 30 Jun 2026
45150254Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Leo Furcht Company insiderDirector · last 7 Oct 20261 · 0
David W. Gryska Company insiderDirector · last 1 Oct 20260 · 0
Brian F. Sullivan Company insiderChief Executive Officer · last 14 Aug 20261 · 0
Lance G. Laing Company insiderChief Science Officer · last 14 Aug 20260 · 0
Vicky Hahne Company insiderChief Financial Officer · last 14 Aug 20260 · 0
BAKER BROS. ADVISORS LP Company insiderOther · last 14 Jul 20260 · 1
Julian Baker Company insiderOther · last 14 Jul 20260 · 1
Polly A. Murphy Company insiderDirector · last 10 Jun 20261 · 0
Richard E. Buller Company insiderDirector · last 10 Jun 20260 · 32
Charles R. Romp Company insiderDirector · last 5 Jun 20260 · 0
David Dalvey Company insiderDirector · last 5 Jun 20260 · 10
Richard Nigon Company insiderDirector · last 5 Jun 20267 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-40.8%
Debt to equityFY 2025 · to 31 Dec 20251.37×
Interest coverFY 2025 · to 31 Dec 2025-11.96×
Share count trendFY 2025 · to 17 Mar 20260.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$165.7M
Free cash flowFY 2025 · to 31 Dec 2025−$153.5M

Analyst forecasts

No analyst forecasts yet.